The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Bernie is currently asymptomatic, with soft tissue metastatic disease. He is 75 years old and has a prostate-specific antigen (PSA) of 27. He is a candidate for sipuleucel-T (Provenge) and its the profile of patients who are known to respond to Provenge-asymptomatic. He is also a candidate for both abiraterone acetate (Zytiga) and enzalutamide (Xtandi). Either of these agents would likely be offered before systemic chemotherapy, because Bernie is asymptomatic and very active.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.